Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets

被引:36
作者
Jin, Ping
Wang, Ena
Provenzano, Maurizio
Deola, Sara
Selleri, Silvia
Ren, Jiaqiang
Voiculescu, Sonia
Stroncek, David
Panelli, Monica C.
Marincola, Francesco M.
机构
[1] NIH, Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA
[2] Univ Hosp ZLF, Dept Surg, Immune Oncol Sect, CH-4031 Basel, Switzerland
关键词
D O I
10.1186/1479-5876-4-26
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Experimentally, interleukin-2 (IL-2) exerts complex immunological functions promoting the proliferation, survival and activation of T cells on one hand and inducing immune regulatory mechanisms on the other. This complexity results from a cross talk among immune cells which sways the effects of IL-2 according to the experimental or clinical condition tested. Recombinant IL-2 (rIL-2) stimulation of peripheral blood mononuclear cells (PBMC) from 47 donors of different genetic background induced generalized T cell activation and anti-apoptotic effects. Most effects were dependent upon interactions among immune cells. Specialized functions of CD4 and CD8 T cells were less dependent upon and often dampened by the presence of other PBMC populations. In particular, cytotoxic T cell effector function was variably affected with a component strictly dependent upon the direct stimulation of CD8 T cells in the absence of other PBMC. This observation may provide a roadmap for the interpretation of the discrepant biological activities of rIL-2 observed in distinct pathological conditions or treatment modalities.
引用
收藏
页数:23
相关论文
共 123 条
[1]  
AHMADZADEH M, 2005, BLOOD
[2]   Defective IL-2-mediated IL-2 receptor α chain expression in Stat3-deficient T lymphocytes [J].
Akaishi, H ;
Takeda, K ;
Kaisho, T ;
Shineha, R ;
Satomi, S ;
Takeda, J ;
Akira, S .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (11) :1747-1751
[3]  
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003897.PUB2
[4]   Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts [J].
Arany, I ;
Tyring, SK ;
Brysk, MM ;
Stanley, MA ;
Tomai, MA ;
Miller, RL ;
Smith, MH ;
McDermott, DJ ;
Slade, HB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1869-1873
[5]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[6]   Update on the role of interleukin 2 and other cytokines in the treatment of patients with Stage IV renal carcinoma [J].
Atkins, MB ;
Regan, M ;
McDermott, D .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6342S-6346S
[7]  
Bacon K, 2002, J INTERF CYTOK RES, V22, P1067
[8]  
Beadling Carol, 2002, Med Immunol, V1, P2, DOI 10.1186/1476-9433-1-2
[9]   Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].
Beutner, KR ;
Geisse, JK ;
Helman, D ;
Fox, TL ;
Ginkel, A ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007
[10]   Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees [J].
Bigger, CB ;
Guerra, B ;
Brasky, KM ;
Hubbard, G ;
Beard, MR ;
Luxon, BA ;
Lemon, SM ;
Lanford, RE .
JOURNAL OF VIROLOGY, 2004, 78 (24) :13779-13792